

GASTROENTEROLOGY

PAPER-III

Time: 3 hours
Max. Marks:100

GASTRO/J/20/10/III

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. What is 16S rRNA? How is it used to study gut flora? List the strengths and weaknesses of this method for studying the gut flora? 2+3+5
2. Involvement of the liver in Covid-19, including its frequency, clinical manifestations, laboratory findings, pathology/pathogenesis and its significance. 1+2+3+2+2
3. a) Define the term 'sarcopenia'. 1+3+6
b) What is the relationship of this condition with chronic liver disease?
c) Discuss the methods for assessment of sarcopenia, and the particular challenges in using these in patients with chronic liver disease.
4. a) Peritonitis associated with continuous ambulatory peritoneal dialysis. 5+5
b) Pseudomyxoma peritonei.
5. A 45-year-old patient underwent ERCP for bile duct stone. She developed acute abdominal pain after 1 hour of the procedure. Discuss: 5+5
a) Differential diagnosis.
b) Management options.
6. a) Immune check point inhibitors. 5+5
b) Vonoprazan.
7. a) How do you classify fundal varices? What are the risk factors for fundal variceal bleeding? 5+5
b) What are the current therapeutic strategies for treating fundal variceal bleeding?
8. Pancreatic cystic neoplasms: 3+4+3
a) Types and imaging features.
b) Approach to a 70-year-old patient with branch duct-IPMN.
c) Surveillance strategy for IPMN.

P.T.O.

GASTROENTEROLOGY

PAPER-III

- | | | |
|-----|---|-------|
| 9. | In relation to Peutz-Jegher's syndrome, indicate: | 2+4+4 |
| | a) The underlying genetic defect and inheritance. | |
| | b) Clinical manifestations. | |
| | c) Management. | |
| 10. | a) CRISPER-Cas 9. | 5+5 |
| | b) Whole exome sequencing. | |
